Effect of Immunocal® With Exercise Versus Casein With Exercise on Aging Processes in Elderly Persons

NCT ID: NCT00935610

Last Updated: 2021-02-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aging is typically associated with a decrease in skeletal muscle mass and muscle function, which contributes decisively to disability in old age and to the loss of quality of life.Resistance exercise can increase muscle strength, function and mass in older adults.

The primary aim of this study is to determine whether the combination of resistance training with a supplementation of a cysteine- rich whey protein isolate (Immunocal) compared to combination of resistance training with casein used as control (casein contains little cysteine) could have the potential to provide a synergic beneficial impact on muscle mass and function which could translate to an improved quality of life in elderly persons.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immunocal

20g of Immunocal

Group Type ACTIVE_COMPARATOR

Immunocal

Intervention Type DIETARY_SUPPLEMENT

20 grams per day of Immunocal for 135 days.

Casein

Intervention Type DIETARY_SUPPLEMENT

20 grams per day for 135 days

Casein

20g of Casein

Group Type PLACEBO_COMPARATOR

Immunocal

Intervention Type DIETARY_SUPPLEMENT

20 grams per day of Immunocal for 135 days.

Casein

Intervention Type DIETARY_SUPPLEMENT

20 grams per day for 135 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunocal

20 grams per day of Immunocal for 135 days.

Intervention Type DIETARY_SUPPLEMENT

Casein

20 grams per day for 135 days

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 65 or older
* Estimated GFR above 45ml/min
* Total bilirubin in the normal range (0.2 to 1.2 mg/dl) AST (10-35 U/L for women and 10-50 U/L for men). ALT equal to or less than 2.5 times the upper limit of normal
* BMI between 18.5-29.9 (kg)/m2
* Sedentary (\< 2 hours of structured exercise)in the last 2 or 3 months
* Based on investigator judgment according to current Canadian guidelines, medical conditions such as hypertension, diabetes and hyperlipidemia have to be stable and optimally controlled before the subject starts the study.

Exclusion Criteria

* History of angioedema or allergic reactions to any compound used in this study.
* Milk protein intolerance
* Subjects currently using N-acetylcysteine, alpha-lipoic acid supplements, or dry whey protein supplements.
* Major surgery in the year prior to testing
* Acute coronary or vascular event within the last year or progressive angina
* Stroke within the past 2 years
* Neurologist and/or orthopedic limitations
* Uncontrolled thyroid or pituitary disease
* Medication which has a major affect on cognitive function
* Signs of early dementia as assessed by Mini-Mental State Examination
* Weight loss of more than 4kg(or more than 5% body weight) over last 6 months
* Alcohol abuse
* Medication which interferes with muscle mass i.e. (corticosteroids)
* Any life threatening conditions based on Investigator judgment.
* Subjects with allergies/intolerance to soya.
* Subjects currently undergoing immunosuppressive therapy.
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Immunotec Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Remi Rabasa-Lhoret, MD. Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Institut de Recherches Cliniques de Montreal

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut de recherches cliniques de Montréal

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Karelis AD, Messier V, Suppere C, Briand P, Rabasa-Lhoret R. Effect of cysteine-rich whey protein (immunocal(R)) supplementation in combination with resistance training on muscle strength and lean body mass in non-frail elderly subjects: a randomized, double-blind controlled study. J Nutr Health Aging. 2015 May;19(5):531-6. doi: 10.1007/s12603-015-0442-y.

Reference Type DERIVED
PMID: 25923482 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AGING-IMM08

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.